COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D PXPX FLVFLV PVP-IPI BUBU BHBH BLBL CICI HC QHC Q NZNZ COCO More..
 
Home   
Share  
  Meta AnalysisMeta
  Global AdoptionAdoption
  Submit FeedbackFeedback
    
  
Database of all ivermectin COVID-19 studies. 104 studies, 67 peer reviewed, 60 with results comparing treatment and control groups. Submit updates/corrections below. FLCCC provides treatment recommendations. Ivermectin related news can be found on Telegram channels BiRD and FLCCC.
 
Search:  
Restrict:    All    Early    Late    Prophylaxis
7/31
Early, Late, PrEP, PEP Covid Analysis (Preprint) (meta analysis) meta-analysis v101 Ivermectin for COVID-19: real-time meta analysis of 60 studies
Details   • Meta analysis using the most serious outcome reported shows 74% and 85% improvement for early treatment and prophylaxis (RR 0.26 [0.16-0.43] and 0.15 [0.08-0.25]), with similar res..
7/28
Meta Popp et al., Cochrane Database of Systematic Reviews, doi:10.1002/14651858.CD015017.pub2 (Preprint) meta-analysis Ivermectin for preventing and treating COVID‐19
Details   Outdated very biased cherry-picking retrospective meta analysis, with a majority of results based on only 1 or 2 studies, showing positive (non-statistically significant) results for 10 of 11 primary outcomes across a total of 13 studies...
7/25
Early Ontai et al., medRxiv, doi:10.1101/2021.07.21.21260223 (Preprint) Early multidrug treatment of SARS-CoV-2 (COVID-19) and decreased case fatality rates in Honduras
Details   Report on the nationwide implementation of multi-drug COVID-19 inpatient and outpatient treatment protocols in Honduras, showing a case fatality rate decrease from 9.33% to 2.97%. No decrease was seen in Mexico, a similar Latin American c..
7/24
News World Ivermectin Day (News) news World Ivermectin Day
Details   Joint event by 22 worldwide organizations.
7/16
News FLCCC Alliance and British Ivermectin Recommendation Development Group (News) news Joint Statement of the FLCCC Alliance and British Ivermectin Recommendation Development Group on Retraction of Early Research on Ivermectin
Details   News release noting that ivermectin remains effective after excluding Elgazzar et al. Given the large magnitude effects and 61 studies, excluding one study with ~3% of patients does not significantly change the evidence base.
7/12
Meta Neil et al., ResearchGate, doi:0.13140/RG.2.2.31800.88323 (Preprint) meta-analysis Bayesian Meta Analysis of Ivermectin Effectiveness in Treating Covid-19 Disease
Details   Bayesian analysis of a subset of ivermectin trial data concluding that there is overwhelming evidence to support a causal link between ivermectin, COVID-19 severity, and mortality.
7/8
News Together Trial (News) news Together Trial removes mortality and adverse event outcomes, and sublingual administration mid-trial
Details   Together Trial removes mortality and adverse event outcomes, and sublingual administration mid-trial.
7/7
Late Hazan et al., medRxiv, doi:10.1101/2021.07.06.21259924 (Preprint) death, ↓85.9%, p=0.04 Effectiveness of Ivermectin-Based Multidrug Therapy in Severe Hypoxic Ambulatory COVID-19 Patients
Details   Small study of 24 consecutive patients in serious condition (9 days post symptoms, mean SpO2 87.4) using combined treatment with ivermectin, doxycycline, zinc, vitamin D, and vitamin C, showing no mortality or hospitalization with treatme..
7/3
News Open Letter, Statement of Concern and Request for Retraction, re: Roman et al. (News) news Open Letter, Statement of Concern and Request for Retraction
Details   Open letter signed by 40 physicians detailing errors and flaws in the Roman et al. meta analysis, and requesting retraction.
7/2
Review Adegboro et al., African Journal of Clinical and Experimental Microbiology, doi:10.4314/ajcem.v22i3.2 (Review) (Peer Reviewed) review A review of the anti-viral effects of ivermectin
Details   Review of the antiviral effects of ivermectin.
7/2
Early Vallejos et al., BMC Infectious Diseases, doi:10.1186/s12879-021-06348-5 (Peer Reviewed) death, ↑33.5%, p=0.70 Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial
Details   RCT with 501 relatively low-risk outpatients in Argentina showing hospitalization OR 0.65 [0.32-1.31]. With only 7% hospitalization, the trial is underpowered. The trial primarily includes low-risk patients that recover quickly without tr..
6/30
Review Turkia, M., ResearchGate, doi:10.13140/RG.2.2.16973.36326 (Review) (Preprint) review A Continuation of a Timeline of Ivermectin-Related Events in the COVID-19 Pandemic [June 30, 2021]
Details   An extension of the ivermectin timeline covering April - June 2021, including WHO's role and funding, Gavi, COVAX, Trusted News Initiative, International Fact-Checking Network, the role of private philantrophy, Frontiers, comparison to th..
6/28
N/A Roman et al., Clinical Infectious Diseases, doi:10.1093/cid/ciab591 (preprint 5/25/21) (Peer Reviewed) (meta analysis) meta-analysis Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials
Details   Severely flawed meta analysis. An open letter signed by 40 physicians detailing errors and flaws, and requesting retraction, can be found at [1]. See also [2]. The authors state that they have no conflicts of interest on medRxiv, however..
6/25
Review Jagiasi et al., The International Journal of Clinical Practice, doi:10.1111/ijcp.14574 (Review) (Peer Reviewed) review Variation in therapeutic strategies for the management of severe COVID-19 in India- A nationwide cross-sectional survey
Details   Survey of medication use for severe COVID-19 in India, showing 33% adoption of ivermectin as of January 2021.
6/22
News Misiones Ministry of Public Health (News) news Results from ivermectin use from the Misiones Ministry of Public Health
Details   News report on ivermectin use in Misiones, Argentina, showing significantly lower hospitalization and mortality, and a dose-dependent effect with improved results for those taking 0.6mg/kg.
6/18
Review Lind et al., Journal of General Internal Medicine, doi:10.1007/s11606-021-06948-6 (Review) (Peer Reviewed) review Increase in Outpatient Ivermectin Dispensing in the US During the COVID-19 Pandemic: A Cross-Sectional Analysis
Details   CDC analysis of ivermectin prescriptions in the US suggesting that, while national health authority recognition is delayed in that country, many physicians are aware of the efficacy demonstrated in clinical trials.
6/18
Early Krolewiecki et al., EClinicalMedicine, doi:10.1016/j.eclinm.2021.100959 (Peer Reviewed) ventilation, ↑151.9%, p=1.00 Antiviral effect of high-dose ivermectin in adults with COVID-19: A proof-of-concept randomized trial
Details   Proof of concept RCT with 30 ivermectin patients and 15 control patients, showing a concentration dependent antiviral activity, but no significant difference in clinical outcomes. There was no significant difference in viral load reductio..
6/17
Meta Bryant et al., American Journal of Therapeutics, doi:10.1097/MJT.0000000000001402 (preprint 3/11/21) (Peer Reviewed) (meta analysis) death, ↓62.0%, p=0.005 Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines
Details   Systematic review, meta analysis, and trial sequential analysis of 24 RCTs finding mortality RR 0.38 [0.19-0.73].